Physician profile
Peilin Wei
NPI 1093999104
$3,648.98
in general payments reported to CMS, 2019-2025
27 companies · $967 in 2025
The $967 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $241 · 2021: $227 · 2022: $722 · 2023: $450 · 2024: $677 · 2025: $967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,094.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $498.62 | 2019-2024 | Lokelma, Farxiga |
| Otsuka America Pharmaceutical, INC. | $472.20 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $281.34 | 2019-2025 | Veltassa, Korsuva |
| Amgen INC. | $268.95 | 2024-2025 | Krystexxa, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $253.28 | 2021-2025 | |
| Travere Therapeutics, INC. | $229.69 | 2023-2025 | |
| Novo Nordisk INC | $166.83 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $148.15 | 2025 | |
| Glaxosmithkline, LLC. | $135.70 | 2021-2024 | Benlysta, Jesduvroq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.39 | 2024-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $119.70 | 2021-2025 | Lupkynis |
| Fresenius USA Marketing, INC. | $112.90 | 2019-2025 | Velphoro, Velphoro |
| Opko Pharmaceuticals, LLC | $108.10 | 2019-2025 | Rayaldee |
| Alexion Pharmaceuticals, INC. | $98.24 | 2023-2025 | Ultomiris |
| Nxstage Medical, INC. | $78.36 | 2019-2023 | Nxstage Pureflow Solution, Nxstage System One |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $72.80 | 2022 | |
| Horizon Therapeutics Plc | $69.86 | 2021-2022 | |
| Daiichi Sankyo INC. | $66.40 | 2020-2023 | Injectafer |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $64.60 | 2024-2025 | Jynarque |
| Laminate Medical Technologies INC. | $63.30 | 2025 | Vasq |
| Akebia Therapeutics INC | $57.88 | 2019-2023 | Auryxia |
| Lilly USA, LLC | $37.58 | 2025 | Jardiance |
| Ardelyx, INC. | $36.98 | 2024-2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $30.94 | 2025 | Terlivaz |
| Kyowa Kirin, INC. | $16.68 | 2023 | Crysvita |
| Cormedix INC. | $14.48 | 2024 | Defencath |
| Covidien Lp | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peilin Wei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.